Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice

Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice

TNO Kwaliteit van Leven
van der Hoorn, J.W.A.
Kleemann, R.
Havekes, L.M.
Kooistra, T.
Princen, H.M.G.
Jukema, J.W.

2007

AIM: This study was designed to investigate the effect of the angiotensin II receptor blocker olmesartan alone, or in combination with standard treatment with a statin, pravastatin, on atherosclerosis development in APOE*3Leiden transgenic mice. METHODS AND RESULTS: Four groups of 15 mice received an atherogenic diet alone (plasma cholesterol 17.4 ± 2.7 mmol/l) or supplemented with either 0.008% (w/w) olmesartan (9.3 mg/kg per day) (plasma cholesterol 16.4 ± 3.9 mmol/l), 0.03% (w/w) pravastatin (35 mg/kg per day) (plasma cholesterol 14.6 ± 2.6 mmol/l), or the combination of both (plasma cholesterol 14.5 ± 2.9 mmol/l) for 6 months. Treatment with olmesartan or pravastatin reduced the development of atherosclerosis as compared to the control group (-46 and -39%, respectively). Pravastatin also reduced the severity of the lesions. As compared to control the combination of both treatments almost fully prevented atherosclerosis (-91%, P < 0.001) and strongly reduced lesion number (-69%), lesion severity (-79%), number of macrophages (-89%) and T lymphocytes (-86%) per cross-section. Treatment with olmesartan alone and in combination with pravastatin inhibited the adhesion of monocytes to the vessel wall (-22%; P < 0.05 and -25%; P < 0.01, respectively), and reduced the relative quantity of macrophages in the lesions (-38%; P < 0.05 and -26%; NS, respectively) as compared to control. CONCLUSION: Olmesartan reduced atherosclerosis development mainly by decreasing monocyte adhesion and the relative amount of macrophages, whereas pravastatin inhibited the progression of atherosclerosis to more advanced lesions, reflecting different anti-atherosclerotic modes of action of the two drugs. Combination therapy with olmesartan and pravastatin additively reduced atherosclerosis development, resulting in less and less severe lesions. © 2007 Lippincott Williams & Wilkins, Inc.

Biomedical Research
APOE*3Leiden mice
Atherosclerosis
Combination therapy
Olmesartan
Pravastatin
T lymphocyte
transgenic mouse
Angiotensin II Type 1 Receptor Blockers
Animals
Apolipoprotein E3
Atherosclerosis
Blood Pressure
Collagen
Diet, Atherogenic
Drug Synergism
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Imidazoles
Inflammation
Lipids
Macrophages
Mice
Mice, Transgenic
Monocytes
Muscle, Smooth, Vascular
Pravastatin
Recombinant Proteins
Serum Amyloid A Protein
T-Lymphocytes
Tetrazoles

http://resolver.tudelft.nl/uuid:726b8137-02a4-4844-904e-fad4edf6b7b1

https://doi.org/10.1097/hjh.0b013e3282ef79f7

240502

0263-6352

Journal of Hypertension, 25 (25), 2454-2462

Hoofdstuk 5 uit proefschrift

article